alitretinoin and Pruritus

Topics: Alitretinoin; Cyclosporine; Humans; Methotrexate; Prurigo; Pruritus

Topics: Alitretinoin; Cyclosporine; Humans; Prurigo; Pruritus; Retrospective Studies

Topics: Adult; Alitretinoin; Cosmetics; Dermatitis, Allergic Contact; Dermatitis, Occupational; Dermatologic Agents; Detergents; Hand Dermatoses; Humans; Male; Occupational Health; Paint; Patch Tests; Pruritus; Recurrence; Secondary Prevention; Steroids; Thiazoles; Treatment Outcome

Chronic itch with secondary scratch lesions such as prurigo has a major impact on quality of life. Due to its relapsing nature and often unknown origin, its treatment is challenging.. We sought to demonstrate that alitretinoin can be an efficacious and well-tolerated treatment in a patient suffering from chronic itch with concomitant prurigo and psoriatic lesions.. Case report.. After 1 month of alitretinoin treatment (30 mg daily), itch as well as prurigo and psoriasis lesions decreased markedly. Three cycles of alitretinoin were administered, as each cessation of treatment led to relapse of the symptoms after 6-8 weeks. Tapering of the alitretinoin dose (30 mg every second day) after the third cycle allowed to maintain the effects for over 18 months.. Treatment of refractory prurigo with alitretinoin might be an efficacious alternative to standard therapies. In case of relapse, retreatment with alitretinoin reinduces a further long-lasting response.

Topics: Alitretinoin; Antineoplastic Agents; Female; Humans; Middle Aged; Prurigo; Pruritus; Psoriasis; Retreatment; Tretinoin

The aim of the CARPE registry is to investigate characteristics and medical care in patients affected by chronic hand eczema. Patients are assessed by dermatological examination and patient questionnaire. Socio-economic and clinical data are collected, and quality of life is measured using the Dermatology Life Quality Index (DLQI). A total of 1,163 patients with chronic hand eczema were eligible for analysis (mean age 47.0 years; 54.6% female; mean disease duration 7.6 years). At inclusion, chronic hand eczema was very severe in 23.4%, severe in 47.0%, moderate in 20.1%, and clear or almost clear in 9.6% of patients. Median DLQI was 8.0. In all, 93.8% of patients reported use of topical corticosteroids, 25.6% systemic antihistamines, 28.3% topical calcineurin-inhibitors, 38.0% ultraviolet phototherapy, and 35.3% systemic treatment (19.7% alitretinoin) prior to inclusion in the registry. A significant proportion of patients may not receive adequate treatment according to the guideline on management of hand eczema.

Topics: Administration, Topical; Adolescent; Adult; Aged; Aged, 80 and over; Alitretinoin; Calcineurin Inhibitors; Chronic Disease; Eczema; Female; Germany; Glucocorticoids; Hand Dermatoses; Histamine Antagonists; Humans; Male; Middle Aged; Occupations; Pruritus; Quality of Life; Registries; Severity of Illness Index; Tretinoin; Ultraviolet Therapy; Young Adult